Doncker P D, Gupta A K, Marynissen G, Stoffels P, Heremans A
Janssen Research Foundation, Beerse, Belgium.
J Am Acad Dermatol. 1997 Dec;37(6):969-74. doi: 10.1016/s0190-9622(97)70074-4.
Itraconazole is a broad-spectrum antifungal agent that has been used to treat dermatomycosis and onychomycosis using continuous therapy. More recently the drug has been used as pulse dosing.
Our purpose was to review the studies in which itraconazole pulse therapy (PT) has been administered in the management of dermatomycoses.
For tinea pedis and manuum, the recommended dosage is itraconazole 200 mg twice daily for 1 week (n = 220). A clinical response and mycologic cure rate of 90% +/- 4% and 76% +/- 6%, respectively, has been obtained. For tinea corporis/cruris, itraconazole 200 mg/day for 1 week (n = 354) resulted in a clinical response and mycologic cure rate of 90% +/- 4% and 77% +/- 6%, respectively. When three pulses of itraconazole are used to treat toenail onychomycosis (n = 1389), the clinical cure rate, clinical response, and mycologic cure rate at follow-up 12 months after the start of therapy were 58% +/- 10%, 82% +/- 3%, and 77% +/- 5%, respectively. With two pulses for onychomycosis of the fingernails, the clinical cure rate, clinical response, and mycologic cure rate at follow-up, 9 months after the start of therapy, were 78% +/- 10%, 89% +/- 6%, and 87% +/- 8%, respectively.
Itraconazole PT is effective and safe in the treatment of tinea pedis/manuum, tinea corporis/cruris, and onychomycosis.
伊曲康唑是一种广谱抗真菌药，一直用于连续治疗皮肤癣菌病和甲癣。最近该药物已被用于冲击疗法。
我们的目的是回顾伊曲康唑冲击疗法（PT）用于治疗皮肤癣菌病的研究。
对于足癣和手癣，推荐剂量为伊曲康唑200mg，每日2次，共1周（n = 220）。临床有效率和真菌治愈率分别为90%±4%和76%±6%。对于体癣/股癣，伊曲康唑200mg/天，共1周（n = 354），临床有效率和真菌治愈率分别为90%±4%和77%±6%。当使用三个疗程的伊曲康唑治疗趾甲癣时（n = 1389），治疗开始后12个月随访时的临床治愈率、临床有效率和真菌治愈率分别为58%±10%、82%±3%和77%±5%。对于指甲癣，使用两个疗程，治疗开始后9个月随访时的临床治愈率、临床有效率和真菌治愈率分别为78%±10%、89%±6%和87%±8%。
伊曲康唑冲击疗法在治疗足癣/手癣、体癣/股癣和甲癣方面有效且安全。
Zotero 插件